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Abstract
The convergence of advances in medical science, human biology, data science and technology has enabled the generation
of new insights into the phenotype known as ‘diabetes’. Increased knowledge of this condition has emerged from popu-
lations around the world, illuminating the differences in how diabetes presents, its variable prevalence and how best
practice in treatment varies between populations. In parallel, focus has been placed on the development of tools for the
application of precision medicine to numerous conditions. This Consensus Report presents the American Diabetes
Association (ADA) Precision Medicine in Diabetes Initiative in partnership with the European Association for the
Study of Diabetes (EASD), including its mission, the current state of the field and prospects for the future. Expert opinions
are presented on areas of precision diagnostics and precision therapeutics (including prevention and treatment) and key
barriers to and opportunities for implementation of precision diabetes medicine, with better care and outcomes around the
globe, are highlighted. Cases where precision diagnosis is already feasible and effective (i.e. monogenic forms of diabetes)
are presented, while the major hurdles to the global implementation of precision diagnosis of complex forms of diabetes
are discussed. The situation is similar for precision therapeutics, in which the appropriate therapy will often change over
time owing to the manner in which diabetes evolves within individual patients. This Consensus Report describes a
foundation for precision diabetes medicine, while highlighting what remains to be done to realise its potential. This,
combined with a subsequent, detailed evidence-based review (due 2022), will provide a roadmap for precision medicine
in diabetes that helps improve the quality of life for all those with diabetes.
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Rationale for precision medicine in diabetes
The practice of medicine centres on the individual. From the
beginning, the physician has examined the patient suffering
from illness, ascertained his/her signs and symptoms, related
them to themedical knowledge available at the time, recognised
patterns that fit a certain category and, based on the practical
wisdom accumulated via empirical trial and error, applied a
given remedy that is best suited to the situation at hand. Thus,
the concept of precision medicine, often defined as providing
the right therapy, for the right patient at the right time, is not
novel. What has changed radically is our ability to characterise
and understand human biological variation through [1] assess-
ment of the genetic and metabolic state, [2] leveraging data to
inform disease categories, and [3] science-guided preventive
and treatment decisions tailored to specific pathological condi-
tions. Coupling these with detailed information about lifestyle
and environment, available through digital devices and technol-
ogies that collect those measures, as well as data abstracted
from electronic medical records, present unparalleled opportu-
nities to optimise diabetes medicine.
Diabetes mellitus is diagnosed by the presence of
hyperglycaemia that is higher than a threshold blood glucose
concentration which predisposes to microvascular end-organ
complications. However, hyperglycaemia is the end-product of
numerous pathophysiological processes that often emerge over
many years and converge on the inability of the pancreatic beta
cells to secrete enough insulin to meet the demands of target
tissues. In clinical practice, absolute insulin deficiency can be
detected from the autoimmune destruction of beta cells in type
1 diabetes, which represents ~10% of all diabetes cases.
Making the diagnosis of type 1 diabetes is critical for survival,
given the therapeutic requirement of exogenous administration
of insulin. However, less commonly, hyperglycaemia might
derive from an inherited or de novo loss of function in a single
gene (e.g. monogenic diabetes, comprising 2–3% of all diabe-
tes diagnosed in children or young adults). Diabetes can also
appear after pancreatitis or organ transplantation, during preg-
nancy or as a result of cystic fibrosis. Most individuals with
diabetes, however, are likely to be diagnosed with type 2
diabetes, which includes defects in one or (more often) multi-
ple physiological pathways (e.g. beta cell insufficiency, fat
accumulation or miscompartmentalisation, inflammation,
incretin resistance, dysfunctional insulin signalling).
Our modern capacity to comprehensively interrogate
diverse axes of biology has facilitated the approach of study-
ing an individual to infer general principles, from which a
discrete treatment plan is selected. These axes include
developmental/metabolic context, genomic variation, chroma-
tin signals that mark genes as active or repressed in tissues,
expressed transcripts, biomarkers of disease and increased
knowledge of lifestyle/environmental risk factors. Parallel
advances in computational power and analytical methods
required to appropriately interrogate ‘big data’ are driving
insights that may radically transform the practice of medicine.
Yet, at this time, the individual physician often lacks the time
and training needed to incorporate these insights into medical
decision making. Thus, the translation of the rapidly accumu-
lating new knowledge into practice requires careful evaluation
and translational strategies involving specialist training,
education and policy considerations.
The failure to adequately understand the diverse molecular
and environmental processes that underlie diabetes and our
inability to identify the pathophysiological mechanisms that
trigger diabetes in individual patients, limit our ability to
prevent and treat the disease. Public health strategies have
struggled to slow the epidemic, even in countries with the
greatest financial and scientific resources. Pharmacological
therapies, comprising 12 different drug classes currently
approved by the US Food and Drug Administration (FDA),
may, at best, control blood glucose andmodify disease course,
but do not provide a cure or result in the remission of disease.
Moreover, these agents are sometimes prescribed based on
non-medical considerations (cost, side effects, patient prefer-
ence or comorbidities), which may overlook the biological
mechanism. Thus, more people are developing diabetes
worldwide and have disease progressing to complications,
incurring a significant healthcare burden and cost.
There are, however, several reasons for hope. First, diabe-
tes caused by single gene defects can be characterised and
targeted therapies are particularly effective [1, 2]. Second, islet
autoantibody biomarkers and genomic risk have clarified
autoimmune diabetes from other forms of the disease [3, 4],
thereby facilitating immune-intervention trials and pre-onset
monitoring to reduce risk of severe complications and aiding
in detection of environmental triggers [5]. Third, multiple
biomarkers and genetic variants have been shown to alter risk
of type 2 diabetes, revealing previously unsuspected biologi-
cal pathways and providing new targets. Fourth, type 2 diabe-
tes has been shown to be a complex combination of multiple
conditions and processes, defined by process-specific
subgroups in which individuals with extreme burdens of risk
in particular pathways reside and for whom a specific thera-
peutic approach may be optimal [6]. Finally, the tools,
resources and data now exist to determine the biological and
lifestyle/environmental predictors of drug response, as
measured by a variety of clinical outcomes [7].
The Precision Medicine in Diabetes Initiative
The idea of precision diabetes medicine is gaining momen-
tum, based upon the promise of reducing the enormous and
growing burden of diabetes worldwide. To address this, the
Precision Medicine in Diabetes Initiative (PMDI) was
launched in 2018 by the American Diabetes Association
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(ADA), in partnership with the European Association for the
Study of Diabetes (EASD). The PMDI has partnered subse-
quently with other organisations (the US National Institute of
Diabetes and Digestive and Kidney Diseases [NIDDK] and
JDRF).
The mandate of the PMDI is to establish consensus on the
viability and potential implementation of precision medicine
for the diagnosis, prognosis, prevention and treatment of
diabetes, through expert consultation, stakeholder engage-
ment and systematic evaluation of available evidence. This
mandate is pursued in order to realise a future of longer,
healthier lives for people with diabetes.
The PMDI is focused on assessing evidence, promoting
research, providing education and developing guidelines for
the application of precision medicine in diabetes. The 2019
ADA Scientific Sessions (held in June 2019) sponsored a
research symposium focused on precision medicine, followed
by a PMDI stakeholder meeting (held in October 2019) that
was attended by experts in areas germane to precision diabetes
medicine from around the world. Future PMDI symposia will
extend the themes of precision diabetes medicine during the
2020 ADA Scientific Sessions and EASDAnnualMeeting. In
the coming years, educational approaches to translate the
science into practice will be the target of a series of postgrad-
uate education symposia. A global clinical research network
focused on precision diabetes medicine is also being planned,
along with other education and information dissemination
activities (see Fig. 1 for an overview of key objectives).
The purpose of the work underlying the ADA/EASD PMDI
consensus reports, of which this is the first, is to define relevant
terminology (Text box 1) and review the current status of diag-
nostics and therapeutics (prevention and treatment) in diabetes,
including key areas of opportunity and where further inquiry is
needed (Text boxes 2–4). Particular focus is placed on eluci-
dating the aetiological heterogeneity of diabetes, which
involves a combination of approaches including contempora-
neous measures of risk factors, biomarkers and genomics, as
well as lifestyle and pharmacological interventions.
Monogenic diabetes is one of few areas where precision
diabetes medicine has been proven feasible and is practised
(as discussed at a recent Diabetes Care Editors’ Expert
Forum; M. C. Riddle, personal communication). This first
Consensus Report does not seek to address extensively the role
of precision medicine in the complications of diabetes, which
is a topic for future evaluation. In addition, we do not discuss
diabetes digital device technology, as this is addressed in a
joint ADA/EASD consensus report [8, 9]. A second PMDI
consensus report will be published documenting the findings
of a systematic evidence review, focusing on precision diag-
nostics and precision therapeutics (prevention and treatment).
An Executive Oversight Committee, comprising represen-
tatives from the founding organisations, ADA (LP) and EASD
(JJN), and the two co-chairs of the initiative (PWF and SSR),
provide PMDI governance. The Executive Oversight
Committee is responsible for ensuring that the PMDI activities
are executed. Leadership and direction of the PMDI are
provided by members of the PMDI Steering Committee,
currently comprised of academic leaders in precision diabetes
medicine from the USA (WKC, JCF, JMN) and Europe
(ATH, MIM, ERP), a representative from NIDDK (CGL)
and the Executive Oversight Committee members (LP, JJN,
PWF, SSR). The Steering Committee is responsible for
providing guidance for PMDI activities and engages in devel-
oping precision diabetes medicine education, drafting consen-
sus statements and building interest/working groups to
achieve its mission. The Executive Oversight Committee
and the Steering Committee work closely together under the
banner of the PMDI Task Force. Membership of the Steering
Committee will expand to include experts from around the
world and across multiple areas of expertise germane to the
topic of precision diabetes medicine.
Work for this Consensus Report began at the October 2019
stakeholder meeting in Madrid. The meeting included presen-
tations and roundtable discussions. At the conclusion of the
meeting, a writing group meeting attended by the PMDI Task
Force and stakeholders was held to determine what should be
addressed in the Consensus Report. Following the meeting,
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Fig. 1 PMDI activity timeline.
RFA, request for applications
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Precision diagnosis
Involves refining the characterisation of the diabetes diagnosis for therapeutic optimisation or to improve prognostic 
clarity using information about a person’s unique biology, environment and/or context.
Precision diagnostics may involve subclassifying the diagnosis into subtypes, such as is the case in MODY, or 
utilising probabilistic algorithms that help refine a diagnosis without categorisation.
Careful diagnosis is often necessary for successful precision therapy, whether for prevention or treatment. This is 
true where subgroup(s) of the population must be defined, within which targeted interventions will be applied and 
also where one seeks to determine whether progression towards disease has been abated.
Precision diagnosis can be conceptualised as a pathway that moves through stages, rather than as a single step. 
The diagnostic stages include (1) an evaluation of prevalence based on epidemiology, including age, or age at 
diagnosis of diabetes, sex and ancestry; (2) probability based on clinical features; and (3) diagnostic tests that are 
interpreted in the light of (1) and (2). A diagnosis in precision medicine is a probability-based decision, typically 
made at a specific point in the natural history of a disease, and neither an absolute truth nor a permanent state.
Precision therapeutics
Involves tailoring medical approaches using information about a person’s unique biology, environment and/or con-
text for the purposes of preventing or treating disease (see ‘precision prevention’ and ‘precision treatment’, below).
Precision prevention
Includes using information about a person’s unique biology, environment and/or context to determine their likely 
responses to health interventions and risk factors and/or to monitor progression towards disease.
Precision prevention should optimise the prescription of health-enhancing interventions and/or minimise exposure 
to specific risk factors for that individual. Precision prevention may also involve monitoring of health markers or 
behaviours in people at high risk of disease, to facilitate targeted prophylactic interventions.
Precision treatment
Involves using information about a person’s unique biology, environment and/or context to guide the choice of an 
efficacious therapy to achieve the desired therapeutic goal or outcome, while reducing unnecessary side effects.
Today, the objective of precision therapy is to maximise the probability that the best treatment of all those available 
is selected for a given patient. It is possible that in the future, precision diabetes medicines will be designed 
according to the biological features of specific patient subgroups, rather than for the patient population as a whole.
Precision prognostics
Focuses on improving the precision and accuracy with which a patient’s disease-related outcomes are predicted 
using information about their unique biology, environment and/or context.
The focus of precision prognostics includes predicting the risk and severity of diabetes complications, patient-
centred outcomes, and/or early mortality.
Precision monitoring
May include the detailed assessment of biological markers (e.g. continuous glucose monitoring), behaviours (e.g. 
physical activity), diet, sleep and psychophysiological stress.
Precision monitoring can be achieved using digital apps, cutaneous or subcutaneous sensors, ingestible sensors, 
blood assays, etc.
The intelligent processing, integration and interpretation of the data obtained through precision monitoring are key 
determinants of success.
Precision monitoring may be valuable for precision prevention (e.g. in type 1 diabetes), precision diagnostics (e.g. 
where diagnoses are based on time-varying characteristics) and precision prognostics (e.g. where disease 
trajectories are informative of the development of key outcomes).
Text box 1: Definitions
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bimonthly calls and electronic communication. Relevant
experts outside of the Task Force were asked to contribute
sections as needed. The Consensus Report was then peer-
reviewed by experts in the field and by the clinical committees
of the founding organisations. The report was then submitted
to Diabetes Care and Diabetologia for simultaneous
publication.
Precision diabetes medicine: what it is
and what it is not
Precision diabetes medicine refers to an approach to optimise the
diagnosis, prediction, prevention or treatment of diabetes by
integrating multidimensional data, accounting for individual
differences (Text box 1). The major distinction from standard
medical approaches is the use of complex data to characterise the
individual’s health status, predisposition, prognosis and likely
treatment response. Precision medicine also focuses on identify-
ing patients who, despite a diagnosis, do not require treatment (or
require less thanmight conventionally be prescribed). These data
may stem from traditional sources such as clinical records, as
well as from emergent sources of ‘big data’, such as individual
medical records from very large cohorts of patients, geomobility
patterns obtained from devices, behavioural monitors (e.g.
actigraphy for exercise and sleep assessments), ingestible, subcu-
taneous or wearable sensors (e.g. for blood glucose monitoring)
and genomic and other ‘omics’ data. Integration of patient
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Type 1 diabetes
Best diagnostic results depend on integrating all diagnostic modalities, not by relying on prior prevalence, clinical 
features or test results in isolation. The age at which the initial islet autoantibody appears and the type of autoantibody 
(e.g. which of the four primary antibodies among ICA512, insulin, GAD and ZnT8) may be important in defining 
aetiological subtypes of type 1 diabetes. The majority of the genetic risk of type 1 diabetes is now known, and the 
sensitivity and specificity of a type 1 diabetes genetic risk score (T1D-GRS) both exceed 80%. Despite this, a high 
T1D-GRS will have low positive predictive value in patient populations where the overall prevalence of type 1 diabetes 
is low, such as those aged >50 years when diabetes is diagnosed. It will likely prove most useful when the T1D-GRS
is combined with clinical features and islet autoantibodies. At present, there is no immune-based test sufficiently repro-
ducible and robust that it can be used diagnostically.
Type 2 diabetes
Cluster analysis at diagnosis can provide insights into likely progression, risk of complications, and treatment response, 
which offer an exciting approach to subclassification of type 2 diabetes. At this time, the available genetic data for type 
2 diabetes do not have sufficient predictive accuracy to replace existing delineative approaches. Although the 
subcategorisation of type 2 diabetes using genetic data are informative regarding the aetiological processes that 
underlie the disease, the methods described so far [6, 101] are not intended to be used to subclassify a type 2 diabetes 
diagnosis nor are the existing genetic data sufficient for this purpose for the majority of individuals with type 2 diabetes. 
Treatment response and progression can be predicted from clinical features [137]. An advantage of using clinical 
features for diagnosis of type 2 diabetes is that they are widely available and easily obtained (e.g. sex, BMI, HbA1c); 
however, a potential limitation is that they may vary over time.
Barriers to implementation
One of several important translational barriers facing the proposed clustering approach for type 1 and type 2 diabetes 
is that a fasting C-peptide measurement is required at the time of diagnosis, which is not routinely performed in clinical 
practice, and the reliability of C-peptide assays varies considerably between laboratories [41]. Another limitation is that 
the biomarkers used to define these clusters change over time depending on the disease course or its treatment, such 
that this approach can only be applied to newly diagnosed individuals, but not to individuals years before disease onset 
or the many millions of people with long-standing diabetes worldwide. Moreover, the current approaches for clustering 
in type 2 diabetes require continuously distributed data to be categorised, which typically results in loss of power. Thus, 
these methods do not yield good predictive accuracy, a major expectation in precision medicine, but this may change 
as the approach is refined.
Research gaps
Based on limited ideal tests and uncertainty in aetiology, more research is needed on type 1 and type 2 diabetes in
order to define subtypes and decide the best interventional and therapeutic approaches.
Text box 2: Precision diagnostics: background, barriers to 
implementation and research gaps    
preferences, patient-centred outcomes, cost-effectiveness and
shared decision making will guide how precision diabetes medi-
cine is formulated and applied.
There are several terms sometimes used interchangeably
with precision medicine, including ‘personalised medicine’,
‘individualised medicine’ and ‘stratified medicine’. The
2020 ADA Standards of Medical Care in Diabetes (ADA
SOC) places considerable emphasis on the personalisation of
diabetes medicine, highlighting that ‘clinicians care for
patients and not populations’ (page S2 of [10]). This reflects
the appreciation of individual differences with respect to
symptomatology, presentation, behaviours, preferences,
social circumstances, response to treatment, comorbidities or
clinical course. For precision diabetes medicine to be effec-
tive, it must be tailored to the individual. Thus, the ADA SOC
instructs the clinician to adapt guidelines to each patient’s
characteristics, circumstances and preferences, including the
patient’s food security, housing and financial stability. In the
context of the PMDI, this is not considered to be precision
medicine; rather, this final step in the process of translating
knowledge into practice is personalised (or individualised)
medicine. In contrast, precision (or stratified) medicine
emphasises tailoring diagnostics or therapeutics (prevention
or treatment) to subgroups of populations sharing similar char-
acteristics, thereby minimising error and risk while
maximising efficacy. Includedwithin precision diabetesmedi-
cine is the monitoring of disease progression using advanced
technologies or considering how patient features affect the
reliability of assays. The application of precision diabetes
medicine may substantially reduce errors in diagnostic
(Fig. 2), therapeutic (Fig. 3) and prognostic (Fig. 4)
processes. For example, the interrogation of large sets
of longitudinal clinical data could identify disease
subtypes and match the patient to others with a similar
disease profile; through knowledge of treatment efficacy
and outcomes, more precise prognosis and optimisation
of therapies for this patient by concordance to similar
subgroups would emerge (Text box 1, Figs 3 and 4).
Type 1 diabetes
In type diabetes, precision prevention mainly involves the optimisation of monitoring methods, thereby facilitating early 
detection and treatment. The reasons most prevention trials in type 1 diabetes have not been effective may include 
failure to consider the individual’s unique type 1 diabetes risk profile (e.g. genetic susceptibility) and their unique 
response to the preventive agent (immune therapy or dietary intervention). Without considering the unique genetic 
profiles of children, interventions aimed at preventing type 1 diabetes (e.g. dietary intervention or immunotherapy) may 
be unlikely to succeed. Thus, precision prevention in type 1 diabetes is likely to involve stratification of at-risk 
populations and innovative monitoring technologies.
Type 2 diabetes
Type 2 diabetes has many avenues for prevention; thus, the possibilities for precision approaches, possibly through 
tailoring of diet, are broad. To date, prevention of type 2 diabetes has focused on people with prediabetes. To be cost-
effective, it will likely be necessary to stratify the prediabetic population such that only those with other relevant risk 
factors are the focus of preventive interventions. Relevant risk factors may include lifestyle, socioeconomic status, 
family history, ethnicity and/or certain biomarker profiles, including genetics.
Barriers to implementation
The effective implementation of precision prevention will require that appropriate technologies are available, the general 
public has the willingness to embrace the approach and that those in greatest need can access precision prevention 
programmes. A communication plan used by the interventionalist and the patient’s perception of risk should be a focus 
of precision prevention strategies.
Research gaps
There are critical areas of research required for implementation of precision prevention in diabetes, including 
determining for whom online care is more effective than in-person care, the types of staff delivering the lifestyle 
modification programmes, the impact of group and/or individual interaction, and the frequency of such sessions. There 
is also uncertainty about how best to provide and sustain lifestyle modification. In addition, emphasis should be placed 
on identifying profiles that indicate the likely response to specific lifestyle interventions (focusing on specific diets, 
exercise programmes and other behavioural factors) and sensitivity to risk factors (such as sleep disturbance, stress, 
depression, poor diet, sedentary behaviours, smoking, certain drugs and obesity).
Text box 3: Precision prevention: background, barriers to 
implementation and research gaps    
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 Type 1 diabetes: The only existing therapy for types 1 diabetes is insulin. Developments in long-acting and glucose-
sensitive insulins are improving the health and well-being of people with type 1 diabetes, as are technological 
advances in continuous glucose monitoring devices, insulin pumps, closed loop systems and the artificial pancreas.
 Type 2 diabetes: It has long been recognised that type 2 diabetes is heterogeneous in its aetiology, clinical 
presentation and pathogenesis. Yet, traditionally, trials of therapeutic intervention do not recognise this variation.
 Monogenic forms of diabetes are already amenable to precision treatment, if correctly diagnosed. For example, 
HNF1A-MODY (MODY3), HNF4A-MODY (MODY1) and ABCC8-MODY (MODY12) are acutely sensitive to the 
glucose-lowering effects of sulfonylureas. Alternatively, individuals with GCK-MODY (MODY2) can have 
unnecessary treatments stopped.
 With increasing efforts to map patients with type 2 diabetes in aetiological space using clinical and molecular 
phenotype, physiology and genetics, it is likely that this increasingly granular view of type 2 diabetes will lead to 
increasing precision therapeutic paradigms requiring evaluation and potential implementation. Genetic variation not 
only can capture aetiological variation (i.e. genetic variants associated with diabetes risk) but also variation in drug 
pharmacokinetics (ADME) and in drug action (pharmacodynamics).
 In contrast, ‘true’ type 2 diabetes is a common, complex disease characterised by thousands of aetiological variants, 
each contributing to a small extent to diabetes risk. Thus, it remains uncertain that genetic variants will be identified 
that are highly predictive of drug outcomes in type 2 diabetes, even if process-specific polygenic risk scores are 
derived (where all variants on an aetiological pathway are combined to increase power).
Barriers to implementation
 The current and growing burden of diabetes is not from Western white populations but from other ethnic groups, in 
particular, South and East Asians. Yet, these populations are under-represented in clinical trials and, in particular, 
in attempts to understand variation in drug outcomes.
 Because the diabetes phenotype can vary markedly by ethnic group, it is likely that complications and drug 
outcomes will differ between populations.
 Many of the approaches gaining traction in precision medicine generate massive datasets that are a burden to store 
and require powerful computational servers for analysis.
 Undertaking appropriately designed clinical trials for precision treatments that meet the current expectations of 
regulatory authorities may be challenging given the many subgroups within which treatments will need to be 
evaluated. Innovative clinical trials will likely be needed and real-world evidence will likely need to be part of the 
evaluation process.
 Translating complex information to patients about genetic (and other omics) tests in a clear, concise and clinically 
relevant manner will require healthcare providers to be appropriately trained.
Research gaps
 For drug outcomes, there is a pressing need to move beyond early glycaemic response and examine variation in 
response in terms of cardiovascular outcomes and mortality rate, especially of the newer agents such as SGLT2i 
and GLP-1RA, with focus on specific patient subgroups. Identifying predictive markers (especially genetic markers) 
of serious adverse events in patients treated with these drugs presents an additional area urgently in need of greater 
attention.
 Need for functional studies to determine the mechanism(s) of action underlying specific gene variants.
 Need for better understanding of the pathophysiology of diabetes to inform on new therapeutic targets.
 Need to study broader populations/ethnic groups.
 Need for understanding outcomes of highest relevance to patients.
 Need for decision support tools to implement precision diabetes medicine in clinical practice.
 Need to demonstrate that approaches are cost-effective.
Text box 4: Precision medicine approaches to treat diabetes: 
background, barriers to implementation and research gaps  
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Precision diagnostics
What are the requirements for precision diagnosis?
Precision diagnostics (Text box 2) employs methods to
subclassify patients to enable the successful application of
precision medicine approaches (Fig. 2). This will facilitate
matching precise prevention strategies and treatments to indi-
viduals either at risk for or diagnosed with diabetes. Ideally, a
precision diagnostic test should be: (1) robust (high test–retest
reliability within and between laboratories); (2) able to define
a discrete subgroup, giving insights into disease aetiology,
prognosis and treatment response; (3) widely available; (4)
easily performed, with accepted norms for interpretation; (5)
inexpensive (or at least cost-effective); and (6) approved by
regulatory authorities.
Precision diagnosis can be conceptualised as a pathway
that moves through stages, rather than as a single step. The
diagnostic stages include assessing the:
& expected prevalence based on epidemiology, including
age, or age at diagnosis of diabetes, sex and ancestry,








A precision diagnosis is a probability-based decision, typically made at a
specific point in the natural history of a disease, and neither an absolute truth
nor a permanent state
Precision diagnostics
Refining the characterisation of diabetes to optimise therapies and/or 
prognostication using information about a person’s unique biology, 
environment and/or context 
Probability scores
Subclassification
Fig. 2 Precision diagnostics
Risk factor avoidance Lifestyle interventions Monitoring Minimise side effects Treatment efficacy
Determine likely responses to health 
interventions and risk factors, optimise
interventions and/or minimise risk factor 
exposures for a given individual
Optimise therapy to achieve 





Tailor therapy (using information about a person’s 
unique biology, environment and/or context) to prevent 
or treat disease
Precision monitoring may include detailed assessments of biological 
markers, behaviour, diet, sleep and psychophysiological stress. Precision 
monitoring may be valuable for precision prevention, precision diagnostics 
and precision prognostics
Fig. 3 Precision therapeutics
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& modification by diagnostic tests that are interpreted in the
light of prevalence and diagnosis.
A diagnosis in precision medicine is a probability-based
decision, typically made at a point in the natural history of a
disease, reflecting neither an absolute truth nor a permanent
state. Presenting the degree of uncertainty in a manner that is
intuitive to the patient and practitioner is critical if the preci-
sion diagnosis is to be effective.
Precision diagnosis in clinical practice
Interpreting HbA1c in diagnosis and monitoring Data and
outcomes from the widespread use of HbA1c, rather than
blood glucose levels, for diagnosis has led to a precision
approach for the diagnosis of diabetes. The level of HbA1c
will depend on factors that impact haemoglobin and red cell
stability as well as average glucose values [10]. Genetic test-
ing can reveal unsuspected variants that alter HbA1c. Thus,
knowledge of the patient’s ancestry and specific genetic infor-
mation can guide interpretation of assay results for diagnosis
and the monitoring of blood glucose.
Diagnosing type 1 vs type 2 diabetes Currently, the most
common step towards precision diagnosis that is made in clin-
ical diabetes medicine is the classification of type 1 vs type 2
diabetes, the two most prevalent subcategories with different
aetiologies and different treatment requirements. Part of the
diagnostic dilemma is that neither type 1 nor type 2 diabetes
are monolithic entities and robust ‘gold standards’ are not
universally agreed. Diagnostic issues arise when expected
clinical features are discordant from established norms (e.g.
people diagnosedwith diabetes who are young and have obesi-
ty, or old and slim, or who are a rare subtype in that clinical
setting) [11]. Islet autoantibody positivity varies by clinical
setting (e.g. in people without diabetes, individuals diagnosed
with probable type 1 diabetes as children, individuals with
clinical features of type 2 diabetes), resulting in an altered prior
probability of type 1 diabetes that reflects the different preva-
lence in these diverse settings. The best diagnosis depends on
integrating all diagnostic modalities, as demonstrated in
predicting long-term C-peptide negativity in individuals diag-
nosed with diabetes between 20 and 40 years of age, where an
integrated model outperformed diagnosis based on clinical
features, circulating antibodies or genetics used in isolation
[3]. The frequency of misdiagnosis of type 1 and type 2 diabe-
tes in middle-aged and elderly adults [11, 12] suggests that
precise diagnostic approaches are needed, especially as failure
to recognise insulin-deficient states can be fatal.
Monogenic diabetes A Diabetes Care Editors’ Expert Forum
(M. C. Riddle, personal communication) has concluded
recently that a monogenic diabetes diagnosis is closest to
meeting all criteria for a perfect diagnostic test as it defines a
discrete subgroup giving insights into aetiology, prognosis
and treatment response [1, 2].Most cases of monogenic diabe-
tes remain misdiagnosed. Perhaps the best example of preci-
sion diabetes medicine is the excellent and long-lasting
glycaemic response to oral sulfonylureas in insulin-
dependent infants diagnosed with neonatal diabetes caused
by abnormalities in the beta cell potassium channel [13–17].
In GCK-MODY (MODY2), it is established that patients do
not require [18], or respond to, oral medication [19]. Other
MODY diagnoses (HNF1A [MODY3], HNF4A [MODY1]
and ABCC8 [MODY12]) are acutely sensitive to the
glucose-lowering effects of sulfonylureas [20–22]; however,
unless the diagnosis is precise, these therapeutic benefits are
lost. With the clear benefits of precision diagnosis of mono-
genic diabetes, it is important to reduce barriers to its imple-
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genetic testing is high and universal testing is not cost-effec-
tive. It is thus necessary to limit testing to those most likely to
have a monogenic diagnosis. Moreover, identification proto-
cols require prescreening based on clinical features (e.g. fami-
ly history, age at onset, phenotype including syndromic
features) and non-genetic testing (islet autoantibodies and C-
peptide).
One approach for implementing precision medicine in the
case of monogenic diabetes would be to:
& test all infants diagnosedwith diabetes in the first 6months
of age, because >80% of neonatal diabetes cases have a
monogenic cause
& use a MODY calculator to identify those whose clinical
features suggest a high likelihood of MODY (www.
diabetesgenes.org/mody-probability-calculator/) [23]
& test individuals with paediatric diabetes when at least three
islet autoantibodies are antibody negative [24]
The effective use of these pregenetic selection criteria
should greatly improve the likelihood of correctly diagnosing
monogenic diabetes without the burden of costly genetic
screens. Although diagnostic molecular genetic testing utilises
robust analysis of germline DNA, which is virtually
unchanged throughout life, there are still issues with its imple-
mentation. One issue is the incorrect interpretation of the
genetic information, leading to inaccurate identification of
causal mutations in both clinical practice and in the published
research literature [25]. Curation of pathogenic variants for
monogenic diabetes is critical and is currently being addressed
by international consortia. As a result of technological
advances, multiple causes of monogenic diabetes can be tested
for in a single next-generation sequencing test. This approach
is generally advantageous as it does mean that syndromic
monogenic diabetes is diagnosed genetically when the patient
presents with isolated diabetes. This will allow other features
to be examined and treated appropriately before clinical
presentation. Examples of this are neonatal diabetes [2],
HNF1B-MODY (MODY5) [26],WFS1 (Wolfram syndrome)
[27] and mitochondrial diabetes [28]. For these patients, the
genetic diagnosis of diabetes will have implications far
beyond the prognosis and care of diabetes, as the patient with
certain types of monogenic diabetes will also be at high risk of
developmental delay, neurological disease, developmental
kidney disease, liver failure, deafness and cardiomyopathy.
Diagnosing latent autoimmune diabetes in adults Latent
autoimmune diabetes in adults (LADA) is not currently
recognised by the ADA as a formal subtype of diabetes.
Nevertheless, LADA reveals some of the difficulties in diabe-
tes subtyping. It was shown that the presence of GAD auto-
antibodies in patients with type 2 diabetes was associated with
progression to early insulin therapy [29]; yet, controversy
remains as to whether LADA is a discrete subtype, a milder
form of type 1 diabetes, or a mixture of some patients with
type 1 diabetes and others with type 2 diabetes. The uncertain-
ty is increased by variation in the diagnostic criteria, with
initial treatment based upon physician preference as well as
the patient’s presentation [30]. In addition, among those with
GAD autoantibodies, the phenotype varies with different
autoantibody levels [31].
Subcategories of common forms of diabetes The
subcategorisation of type 1 or type 2 diabetes may not always
be the optimal approach for precision diabetes diagnosis or
therapy. Nevertheless, the ability to delineate type 1 or type
2 diabetes using non-traditional data and approaches may lead
to improvements in prevention or treatment of the disease,
including diabetes subclassifications beyond type 1 or type 2
diabetes.
Subcategories in type 1 diabetes The age at which the initial
islet autoantibody appears and the type of autoantibody
(e.g. which of the four primary antibodies among islet cell
autoantigen 512/islet antigen 2 [ICA512/IA-2], insulin,
GAD, zinc transporter 8 [ZnT8]) may be important in
defining aetiological subtypes of type 1 diabetes [32].
Data supporting this potential subcategory are based upon
those diagnosed in the first 10 years of life and in
predominantly white European populations. The relevance
to other ethnic groups and those diagnosed later in life is
uncertain.
The genetic variants accounting for the majority of risk of
type 1 diabetes are now known, and the sensitivity and
specificity of type 1 diabetes genetic risk scores (T1D-
GRS) both exceed 80% [5, 33–35]; however, a high T1D-
GRS will have low positive predictive value in populations
with a typically low prevalence. A T1D-GRS may prove
most useful when integrated with clinical features and islet
autoantibodies [3, 4]. There is variation in the genetic
susceptibility with age at diagnosis but, at present, genetics
is not suggested as an approach for defining subtypes of
type 1 diabetes.
There is strong evidence for enrichment of immune cell
types that are associated with genetic risk of type 1 diabetes,
particularly T cells (CD4+ and CD8+) and B cells (CD19+).
However, at present, there is no immune-based test sufficient-
ly reproducible and robust that it can be used diagnostically
for type 1 diabetes.
Persistent endogenous beta cell function in type 1 diabetes
is associated with greater potential for improved glycaemic
control and reduced complications [36]. A stimulated C-
peptide measurement represents a candidate for defining
subcategories of type 1 diabetes with different treatment aims.
C-peptide levels exponentially fall in the ‘honeymoon period’
after type 1 diabetes diagnosis [37] but have been shown to be
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stable 7 years after diagnosis [38]. Persistent C-peptide is
associated with a later age at diagnosis, although there are
few data to predict those likely to maintain high levels of C-
peptide.
Subcategories in type 2 diabetes Family history of type 2
diabetes, as a surrogate for precise genetic evaluation,
fails to meet many of the criteria of a robust test, as any
assessment changes over time and depends on the rela-
tives selected for reporting the ‘family’. The value of a
family history may be greatest in monogenic diabetes, in
which a pedigree will often demonstrate a pattern of
inheritance consistent with a single gene disorder and a
consistent phenotype.
Type 2 diabetes treatment response and disease progres-
sion can be predicted from continuous clinical features
with specific models. These models appear to perform
better than dividing into cluster-based subgroups [7]. An
advantage of using clinical features is that they are widely
available and easily obtained (e.g. sex, BMI, HbA1c).
However, they are limited by the fact that clinical features
may vary over time and with the natural history of the
disease. Incorporation of longitudinal change with treat-
ment response could be a strength as the model’s predic-
tion would change in concert with changes in the pheno-
type of the patient.
Recent research has attempted to define subcategories of
type 2 diabetes (and type 1 diabetes) based on cluster analysis
at diagnosis to provide insights into likely progression, risk of
complications, and treatment response [39, 40]. Barriers
facing this and other approaches include collection of data that
are not routinely obtained (e.g. a fasting C-peptide at the time
of diagnosis, with considerable variation in results between
laboratories [41]) and the change in biomarkers over time that
are dependent on disease course or its treatment. Genetic data
have been used to define type 2 diabetes subcategories by
clustering genetic variants that associate with physiological
traits and which are correlated with clinical outcomes [6]. At
this time, the available genetic data for type 2 diabetes and the
clustering does not have sufficient predictive accuracy to
replace existing delineative approaches. None of the methods
described above are established for subclassification of type 2
diabetes in clinical practice; nevertheless, it is true that in a
minority of patients, their specific type of diabetes may be
adequately characterised using genetic clustering [42, 43].
Precision therapeutics
Accurate diagnosis is necessary for successful precision ther-
apy, whether for prevention or treatment (Fig. 3). This is true
where subgroup(s) of the population must be defined to deter-
mine which targeted interventions will be applied, as well as
for determination of treatment outcome. In monogenic diabe-
tes, there are no currently known options for prevention. In
type 1 diabetes, precision prevention currently involves main-
ly the optimisation of monitoring methods (Text box 3), there-
by facilitating timely early detection, preventing early compli-
cations and allowing appropriate treatment. In contrast, type 2
diabetes has many avenues for prevention; thus, the possibil-
ities for precision approaches, possibly through tailoring of
lifestyle (e.g. diet), are broad in type 2 diabetes.
Precision prevention in diabetes (Text box 3)
Type 1 diabetes Type 1 diabetes is characterised by damage,
impairment and eventual destruction of the insulin-producing
pancreatic beta cells, thought to be the result of an autoim-
mune process. Type 1 diabetes progression has been grouped
into discrete ‘stages’ [44]: Stage 1 is defined by the presence
of ≥2 islet autoantibodies, with normal blood glucose; Stage 2
is defined by the presence of ≥2 islet autoantibodies with
elevation of blood glucose, signalling the functional impair-
ment of the beta cells; and Stage 3 is characterised by symp-
toms of dysglycaemia, such as polyuria or diabetic
ketoacidosis, although not all symptoms need be present. A
clinical diagnosis of type 1 diabetes typically is not given until
Stage 3. Type 1 diabetes is nearly inevitable once ≥2 islet
autoantibodies appear, particularly in those of younger age,
with a lifetime diabetes risk approaching 100% [45, 46].
Approximately half of the risk of type 1 diabetes is due to
genetic factors, with over 30% of the genetic risk attributable
to genes of the HLA complex, but also including more than 50
non-HLA loci [35]. Unknown environmental factors are
thought to trigger the autoimmune process that results in initial
beta cell damage and progression toward symptomatic type 1
diabetes [47].
Primary prevention trials in genetically susceptible individ-
uals who have not yet developed autoantibodies (i.e. pre-stage
1) and secondary prevention trials in children with stages 1
and 2 have been conducted [48] using dietary interventions
and immune-targeting approaches. Dietary manipulation stud-
ies have been largely unsuccessful in reducing islet autoim-
munity [49–51] or type 1 diabetes [52]. Previous intervention
studies among individuals at stage 1 or stage 2 have been
unable to slow, halt or reverse the destruction of insulin-
producing beta cells. Of nine completed secondary prevention
trials [53–60], only one (using an anti-CD3 antibody) has
shown a slight delay in progression to type 1 diabetes [61].
Most prevention trials in type 1 diabetes have not been
effective, partially because the unique type 1 diabetes genetic
risk profile of the individual and their unique response to the
preventive agent (immune therapy or dietary intervention)
have not been considered. For example, the inflammatory
response to infection with enteroviruses implicated in the
onset of type 1 diabetes has been shown to be genetically
1681Diabetologia (2020) 63:1671–1693
mediated [62] and diet has had different effects on develop-
ment of autoimmunity and progression to type 1 diabetes [63]
dependent on genetic risk. Several studies have suggested that
susceptibility to islet autoimmunity and progression to type 1
diabetesmay be related to the ability to adequately use vitamin
D, as higher cord blood 25-hydroxyvitamin D was associated
with a decreased risk of type 1 diabetes, but only in children
who were homozygous for a vitamin D receptor gene (VDR)
variant [64]. Risk of islet autoimmunity was observed with
reduced dietary intake of the n-3 fatty acid α-linolenic acid,
but only in those with a specific genotype in the fatty acid
desaturase gene (FADS) cluster [65]. Thus, without consider-
ing the unique genetic profiles of children, dietary supplemen-
tation may not be successful, arguing for an appropriately
validated precision approach.
Type 2 diabetes The emergence of type 2 diabetes as a global
public health crisis during recent decades has motivated
numerous large randomised controlled trials assessing the effi-
cacy of pharmacological or lifestyle interventions for preven-
tion. An emphasis has been placed on intervening in people
with ‘prediabetes,’ defined as a person with levels of fasting
blood glucose, 2 h blood glucose or HbA1c that are chronically
elevated but below the diagnostic thresholds for diabetes.
Although prediabetes is a major risk factor for type 2 diabetes
and other diseases [66], intervening in everyone with predia-
betes may not be cost-effective [67]. Aggressive precision
prevention in those with relevant risk factors is discussed in
the current ADA SOC [68]. Youth with prediabetes should be
the focus of preventive interventions, especially those with
overweight or obesity and who have one or more additional
risk factors (e.g. maternal history or exposure to gestational
diabetes mellitus [GDM], a positive family history of diabetes
in first- or second-degree relatives, signs of insulin resistance
or specific high-risk ancestry).
Multiple interventions in adults with type 2 diabetes have
been evaluated for risk reduction and prevention, both in the
short and the long term. A recent systematic review [69]
reported that after active interventions lasting from 6 months
to >6 years, relative risk reduction achieved from lifestyle
interventions (39%) was similar to that attained from use of
drugs (36%); however, only lifestyle interventions had a
sustained reduction in risk once the intervention period had
ended. Analysis of the post-intervention follow-up period
(~7 years) revealed a risk reduction of 28% with lifestyle
modification compared with a non-significant risk reduction
of 5% from drug interventions.
Most lifestyle intervention programmes use standardised
approaches designed to change diet and exercise habits for reduc-
ing body weight. The Diabetes Prevention Program (DPP) eval-
uated the efficacy of lifestyle intervention and metformin thera-
py, compared with standard of care and placebo (control), for
delay or prevention of diabetes in those with impaired glucose
regulation at baseline. Although the reductions in diabetes risk
from lifestyle (58% reduction) and metformin (31% reduction)
compared with the control intervention were impressive [70],
there was considerable variation across the study population
[71], with many participants developing type 2 diabetes during
the active intervention period (the first 2.8 years of the trial).
Thus, the DPP lifestyle intervention did not truly ‘prevent’ diabe-
tes. Indeed, in the decade after randomisation, during which
participants were offered lifestyle reinforcement semi-annually,
the average duration before disease onset was ~3 years [72].
Those participants in the DPPwho progressed most rapidly were
those who lost the least weight in the early stages of the inter-
vention [73], with genetic variants representing significant
predictors of peak weight loss and weight loss maintenance
[74]. Results from the DPP and other large prevention trials
suggest that a ‘one-size-fits-all’ lifestyle intervention strategywill
not be efficacious for everyone, particularly if it cannot be
sustained, strengthening the case for precision lifestyle interven-
tions in type 2 diabetes prevention.
Although precision diabetes medicine is much more than
genetics, the majority of relevant research has focused on
evaluating the role of genetic variants in precision prevention.
Large epidemiological studies [75] and intervention trials [76,
77] strongly suggest that standard approaches for lifestyle
modification are equally efficacious in preventing diabetes
regardless of the underlying genetic risk. This contrasts the
extensive epidemiological evidence suggesting that the rela-
tionship of lifestyle with obesity is dependent on genetic risk
[78–81]; however, with few exceptions (e.g., [74]), analyses
in large randomised controlled trials have failed to show that
these same genetic variants modify weight loss in response to
lifestyle intervention [82]. It is also important to recognise that
knowledge of increased genetic risk for diabetes may not
motivate improvements in lifestyle behaviours. Indeed,
knowledge of increased genetic risk for diabetes may decrease
motivation to modify behaviour in genetic fatalists [83].
Diet recommendations optimised to the individual have been
shown to reduce postprandial glycaemic excursions to a greater
extent than standard approaches in healthy individuals [84].Meal
compositions that induce the most favourable glycaemic profiles
have been guided bymodels derived from an individual’s biolog-
ical data (e.g. microbiome, genome, and metabolome), informa-
tion on lifestyle factors (e.g. sleep and exercise) and postprandial
glycaemia following the consumption of a series of standardised
meals. Although these studies indicate that personalised diet
plans may help to minimise postprandial glycaemic excursions,
no studies have reported the long-term impact of adhering to
personalised diets on glycaemic control.
Of the 12 approved classes of diabetes drugs, many having
been assessed for efficacy in prevention. Overall, drugs that
enhance insulin action have proven more effective in diabetes
prevention than those that increase insulin secretion. Some of
the variability in the diabetes-reducing effect of metformin in
1682 Diabetologia (2020) 63:1671–1693
the DPP has been associated with variation in the SLC47A1
gene that encodes the multidrug and toxin extrusion 1
(MATE1) transporter protein [85]. In the DPP Outcomes
Study, the effects of lifestyle, metformin and placebo inter-
ventions on weight reduction during the 6–15 years that
followed the end of the randomised intervention phase were
assessed [86]. As a percentage of baseline weight, those
assigned to metformin maintained an average weight loss of
6.2% compared with the lifestyle intervention group, which
maintained a weight loss of 3.7%, and the placebo group,
which maintained a weight loss of 2.8%. In the subgroup of
DPP participants who lost <5% baseline weight at 1 year post
randomisation (poor responders), body weight during the
following 14 years remained essentially unchanged, whether
receiving metformin or placebo interventions. In contrast,
those participants in the lifestyle intervention group who lost
<5% baseline weight gained and sustained ~2 kg excess body
weight in the years that followed. These findings reveal a
subgroup of DPP participants in whom lifestyle intervention
led to weight gain, which presents a potential avenue for strat-
ified intervention, where individuals who are unlikely to
respond well to lifestyle modification might be better served
by other therapeutic approaches.
Precision treatment (Text box 4)
Once diabetes develops, a variety of therapeutic steps may be
clinically indicated to improve disease management. These
steps include:
& glucose monitoring
& patient education and lifestyle intervention [87]
& surgery
& drug treatments to lower HbA1c
& drug treatments to lower cardiovascular risk (e.g. statins,
anti-hypertensives)
& drug treatments targeting specific complications (e.g.
ACE inhibitors/angiotensin II receptor blockers [ARBs]
and sodium–glucose cotransporter 2 [SGLT2] inhibitors
for proteinuric kidney disease, fibrates for retinopathy,
atypical analgesics for painful neuropathy, and statins
and antihypertensives for cardiovascular disease).
For each of these treatments, there will be patients who
respond well and those who respond less well, in addition to
those who have adverse outcomes from the therapy. Thus,
precision treatment can be considered as using patient charac-
teristics to guide the choice of an efficacious therapy to
achieve the desired therapeutic goal or outcome while reduc-
ing unnecessary side effects (Fig. 3). Given the broad scope of
precision treatment, pharmacological therapy in type 2 diabe-
tes has the best evidence-base for precision therapeutics at
present.
Subcategories and drug outcomes
Traditionally, trials of therapeutic interventions do not recog-
nise variation in aetiological processes that lead to the devel-
opment of type 2 diabetes. The MASTERMIND consortium
recently re-analysed data from the A Diabetes Outcome
Progression Trial (ADOPT) and Rosiglitazone Evaluated for
Cardiac Outcomes and Regulation of Glycaemia in Diabetes
(RECORD) studies in order to highlight how clinical pheno-
type can be used to help guide treatment intervention. In
ADOPT, on average, men without obesity showed a greater
HbA1c reduction over 5 years with sulfonylureas than they did
with thiazolidinediones; however, women with obesity treated
with thiazolidinediones had sustained HbA1c lowering over
the 5 years compared with sulfonylureas [88]. When consid-
ering the clinical and physiological variables used to subgroup
individuals with diabetes [39], the insulin-resistant cluster
defined in ADOPT and RECORD responded better to
thiazolidinediones while the older patient cluster responded
better to sulfonylureas [7].
Similar studies have been undertaken to investigate how
simple clinical variables can be used to predict glycaemic
response to dipeptidyl peptidase 4 inhibitors (DPP4i). In stud-
ies undertaken using prospective (Predicting Response to
Incretin Based Agents in Type 2 Diabetes study [PRIBA])
and primary care data in the UK (Clinical Practice Research
Datalink [CPRD]), an insulin-resistant phenotype of obesity
and high triacylglycerols was associated with reduced initial
response to DPP4i, and more rapid failure of therapy [89].
As outlined under ‘Precision diagnostics’ and elsewhere,
the most current examples of how genetics impacts precision
treatment can be seen in monogenic diabetes, for which single
gene mutations are causal for the development of diabetes and
for which targeted treatments can, in effect, bypass the
aetiological defect (e.g. sulfonylurea sensitivity in HNF1A-
MODY [MODY3] [20] and insulin independence with high-
dose sulfonylureas in neonatal diabetes due to KATP channel
defects [14]). In some instances, precision treatment may
result in cessation of unnecessary medication, as is the case
in people withGCK-MODY (MODY2), where blood glucose
remains somewhat elevated, but stable, over time.
Unlike monogenic forms of diabetes, type 2 diabetes is a
common complex disease characterised by thousands of
aetiological gene variants. It is uncertain whether individual
genetic variants will be highly predictive of drug outcomes.
Similar to the underlying genetic architecture of type 2 diabe-
tes, it is possible that drug response in type 2 diabetes will be
influenced by many genetic variants of small to modest effect.
Genetic studies of drug response in type 2 diabetes have large-
ly been based on candidate genes of known aetiological
processes or drug pathways. These studies have been limited
in their success. For example, some studies have shown that
the KCNJ11/ABCC8 E23K/S119A risk variant increases
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glycaemic response to sulfonylureas [90–92]; in contrast, the
TCF7L2 diabetes risk variant reduces glycaemic response to
sulfonylureas [93–95]. The PPARG Pro12Ala diabetes risk
variant has been associated with reduced glycaemic response
to thiazolidinediones [96–98].
Genome-wide association studies (GWAS) have the poten-
tial to provide novel insights as they make no assumptions
about drugmechanism or disease process, in contrast to candi-
date gene/pathway studies. Only GWAS of metformin have
been reported to date [99, 100], identifying that variants at the
ATM/NPAT and SLC2A2 loci are associated with an altered
glycaemic response. In SLC2A2, the non-coding rs8192675
variant C allele is associated with greater response to metfor-
min and is associated with reduced expression of the SLC2A2
transporter in liver, intestines and kidneys. In individuals with
obesity, those with two copies of the C allele had an absolute
HbA1c reduction of ~1.55% (compared with a reduction of
~1.1% in those without the C allele). While this may appear
to be a small difference, the SLC2A2 genotype effect is the
equivalent of a difference in metformin dose of 550 mg, or
about half the average effect of starting a DPP4i.
When considering aetiological variation, recent work
partitioning diabetes-associated genetic variants by their
presumed aetiological process (partitioned polygenic scores)
[6, 42, 101] may define genetically driven dominant process-
es. These processes, such as beta cell dysfunction,
lipodystrophy or obesity could respond differently to drugs
that act on these pathways, such as sulfonylureas, glucagon-
like peptide 1 receptor agonist (GLP-1RA), DPP4i and
thiazolidinediones.
Genetic variation can not only capture aetiological varia-
tion but also variation in drug pharmacokinetics (absorption,
distribution, metabolism, excretion [ADME]) and in drug
action (pharmacodynamics). Studies of ADME genes have
revealed some variants with a moderate to large effect. For
example, the 8% of the white population who carry two loss-
of-function variants in CYP2C9 are 3.4 times more likely to
achieve HbA1c target than those with normal function cyto-
chrome P450 family 2 subfamily C member 9 (CYP2C9), due
to reduced metabolism of sulfonylureas and increased serum
concentrations [102]. SLCO1B1 and CYP2C8 genotypes that
alter liver uptake and metabolism of rosiglitazone can alter
glycaemic response (HbA1c) by as much as 0.7% [103].
While these studies have promoted pharmacogenetic
approaches in precision diabetes therapeutics, some
studies have been surprisingly negative. For example,
loss-of-function variants in the SLC22A1 gene, encoding
the organic cation transporter 1 (OCT1), which trans-
ports metformin into the liver [104, 105], do not reduce
the glucose-lowering efficacy of metformin in patients
with type 2 diabetes [106, 107]. Thus, there is genetic
evidence that metformin does not work to lower glucose
solely via hepatic mechanisms.
The diabetes phenotype is markedly different across ethnic
groups; thus, it is likely that drug outcomeswill differ between
populations. The current and growing burden of diabetes is
growing rapidly in all populations, particularly in South and
East Asians, yet, these populations are under-represented in
clinical and drug outcomes trials. A lack of systematic reviews
and meta-analyses from these high-prevalence regions still
points to differences in drug response. For example, the
DPP4i response is greater in Asian than white people [108],
a result supported by a subgroup analysis of the Trial
Evaluating Cardiovascular Outcomes with Sitagliptin
(TECOS) showing a greater HbA1c reduction to sitagliptin
in East Asians compared with white individuals [109].
Glycaemic response to metformin has also been reported to
differ by ethnic group, with African-American individuals
having a greater response than European Americans [110].
At this time, it is evident that we have the potential to use
simple clinical (e.g. BMI, sex, ethnicity), physiological and
genetic variables to predict who is more or less likely to bene-
fit from a treatment. The reducing costs of genotyping panels
mean that genotype information could potentially be available
at the point of prescribing, when the modest effect sizes
described may start to have clinical utility. There is a need to
develop implementation and evaluation strategies to assess the
effectiveness and cost-effectiveness of such approaches
compared with conventional treatment approaches.
Precision approaches to diabetes
in pregnancy
In women, being affected by GDM is a major risk factor for
type 2 diabetes. The risk of developing type 2 diabetes in
women with prior GDM approaches 70% after the index preg-
nancy [111], climbing to an 84% risk of developing type 2
diabetes in women of East Indian ancestry [112]. Currently,
genetic studies of GDM have identified those variants known
to increase risk of type 2 diabetes [113]; however, other vari-
ants have been shown to influence glycaemic traits specifical-
ly in pregnancy [114]. Furthermore, like type 2 diabetes,
GDM is a heterogeneous condition linked to primary defects
in either insulin secretion or sensitivity [115, 116]. GDM can
also result from monogenic forms of diabetes, as numerous
studies have shown. Models that attempt to predict pregnancy
complications [117] or subsequent type 2 diabetes [118] in
GDM using clinical characteristics, biomarkers and/or genetic
variants have yet to be adopted, even though both lifestyle
interventions and metformin use have demonstrated benefits
in reducing the risk of type 2 diabetes in women with prior
GDM [119].
The target for all patients with type 1 or type 2 diabetes in
pregnancy is to achieve as near normal glucose as possible,
particularly around the time of conception (to reduce
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developmental anomalies) and in the third trimester (to reduce
the risk of macrosomia) [120]. In pregnancy, the only clear
exception so far is for mothers with GCK-MODY (MODY2)
as fetal growth is determined predominantly by fetal genotype
[121]. In mothers whose fetus inherits the mother’s GCK-
MODY mutation, fetal growth is normal despite the maternal
hyperglycaemia; thus, t reatment of the maternal
hyperglycaemia is not recommended [121, 122].
Establishingwhether the fetus is likely to be affected is usually
determined by ultrasound scan. In the future, the use of non-
invasive cell-free DNA methods in maternal blood will likely
establish fetal risk [123]. In GDM, whether maternal
hyperglycaemia is closely monitored and treated in the third
trimester is based on the degree of hyperglycaemia determined
by an oral glucose tolerance test at 24–28 weeks’ gestation
[10]. In the future, this decision could be modified by non-
glycaemic factors that impact fetal growth.
Patient-centred mental health
and quality-of-life outcomes
Precision diabetes medicine holds the promise of reducing
uncertainty by providing therapies that are more effective, less
burdensome and with fewer adverse outcomes, which ulti-
mately improve quality of life and reduce premature death
(see Text box 5). Highly relevant in this context is mental
health (e.g. risk of distress and depression), yet little has been
done to investigate how precision medicine might play a
useful role in improving mental health outcomes.
Depression and anxiety are twice as common in people
with diabetes than in the general population, occurring in up
to 20% of adult patients [124]. Distress occurs in ~30% of
people with diabetes [125], reflecting the emotional and
psychological burden that comes with diabetes and its compli-
cations, the life adjustments it requires, and anxiety about
hypoglycaemia or the impact on the fetus for GDM. Distress
has been reported as being more common in patients in
secondary, rather than primary, care and in populations with
non-European ancestry. Depression is more common in
lower- and middle-income countries, where ~75% of people
with type 2 diabetes reside [125]. Both depression and distress
in diabetes are more common in those who progress from oral
agents to insulin therapy [126]. The onset of complications
with the initiation of a more complex pattern of treatment is
associated with increased rates of depression [126].
There are key points in the life course of a person with
diabetes when both rational and irrational fears are often
elevated, typically coinciding with ‘events’, including:
& increased medication dose
& transition to insulin or other injectables or devices
& emergence of complicat ions or worsening of
complications
& following a severe hypoglycaemic event
& change in diabetes care provider.
In many cases, patient self-evaluations may be distorted at
these times because the patient attributes blame for the disease
to his/her self, the future feels uncertain and distress peaks. In
the setting of precision diabetes medicine, providers should
assess symptoms of diabetes distress, depression, anxiety,
disordered eating and cognitive capacities using appropriate
standardised and validated tools at the initial visit, at periodic
intervals and when there is a change in disease, treatment or
life circumstance [127], information that, when combined
with other data, are likely to improve the precision of clinical
decision making.
Psychological counselling can help patients understand and
manage their emotional reactions to major events by develop-
ing a more optimistic outlook and more realistic, modulated
and adaptive emotional reactions [128]. Precision medicine
may be used in the future to help predict the frequency and
extent of emotional crises. As a result, precision diabetes
medicine may lessen the patient burden, help patients to
objectivise their disease, and provide targets for behavioural
and point-of-care interventions at critical moments in the clin-
ical care cycle. Effective and tailored education and profes-
sional counselling will be necessary to mitigate the risk that a
clearer prognosis may raise anxiety about the future for some
patients.
Equity in precision diabetes medicine
The experience with monogenic diabetes has shown that there
is a large degree of regional, national and international varia-
tion in how, and how often, these cases are diagnosed [1, 129,
130]. This variation is, in part, due to differences in access to
general medical care and treatments, access to relevant
healthcare professionals with the necessary education, training
and experience, and access to laboratories with the necessary
experience, assays and standards [131]. A precision approach
to diabetes care will require that the relevant laboratory
methods and assays are carefully standardised and compara-
ble. Assessments that need to be standardised include:
& type 1 diabetes-associated autoantibodies
& C-peptide
& clinical genetic/genomic risk scores
& decision-support interpretation
One challenge to standardisation is that the frequency of
various diabetes phenotypes and risk genotypes may vary by
regions of the world and between ethnicities within a region.
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For example, type 2 diabetes often manifests very differently
in Native Americans than in people of European ancestry,
with Native Americans tending to develop diabetes at a much
younger age and experience loss of beta cell function earlier in
the life course of the disease [132]. Recent insights following
the ADA Precision Diabetes Medicine meeting in Madrid
(held in October 2019) confirm that case-based interactive
learning is an excellent way to support this type of postgrad-
uate education for clinicians at all levels of training.
The road to implementation
Advances in science allow for generation of large-scale biolog-
ical and physiological data that can be harnessed for precision
diagnostic (Fig. 2), therapeutic (Fig. 3) and prognostic (Fig. 4)
purposes. Programmes are needed to train, foster and retain
individuals with biological and data science expertise who will
contribute to precision diabetes medicine efforts. Furthermore,
clinicians, scientists and regulators must collaborate to develop
standards and safeguards for protecting the accumulated
‘precise’ data, which in some instances may lead to unintended
and sensitive revelations, on individuals in a secure manner
across populations and across countries.Worldwide differences
in prevalence of the forms of diabetes necessitates inclusion of
currently understudied populations for the development of
precision diagnostics and therapeutics. As a result, the precise
subtype of diabetes a particular individual is diagnosed with
may vary in different populations based on subtype frequency
or genetic or dietary or lifestyle differences.
The communication strategy used by the interventionalist
and the patient’s perception of risk may be important factors
contributing to the successful implementation of precision
diabetes medicine. Both personal and societal barriers may
exist to the implementation of precision prevention across
geographic regions and countries. Discussions with global
and regional regulatory agencies will be needed to determine
the level of evidence needed for approval and adoption of
precision diagnostics and therapeutics. The development of
tools and strategies to synthesise patient data and facilitate
Diagnosis and disease management
A more specific diagnosis has the potential to reduce uncertainty and manage future expectations about disease 
course. This is clearly the case for some monogenic forms of diabetes, where diagnosis is nearly certain given its 
strong genetic indication and the specific treatment is coupled to the subcategory (genetic subtype) of disease. 
Emerging knowledge regarding subtypes of type 2 diabetes indicates that there is potential to classify individuals with 
diabetes at risk for progression to complications.
Misdiagnosis
Inaccurate classification of the type of diabetes, either from lack of precision or inadequate clinical attention to detail at 
the time of presentation, can have long-lasting adverse effects on mental health and quality of life. In the paediatric and 
younger adult population, the risk of misclassification is increasing as both ‘true’ type 1 diabetes and ‘true’ type 2 
diabetes classifications are confused through the growing obesity epidemic in youth (type 2 diabetes) and older ages 
at onset (type 1 diabetes). In addition, monogenic variants of diabetes can be misdiagnosed as either type 1 or type 2 
diabetes. A precision approach to diagnosis with appropriate standardised laboratory support and increased research 
to obtain novel biomarkers of disease has the potential to solve this problem.
Complications
Worry about complications is an issue for all people with diabetes. Currently, people with diabetes (either type 1 or type 
2 diabetes) are given a label of being unequivocally at risk of reduced lifespan, amputation, kidney failure and blindness. 
A more precise diagnosis, prognosis, and strategy to predict and prevent complications has the potential to greatly 
reduce disease burden and distress and improve quality of life. Nevertheless, there is also a risk that more precise 
prognostification may cause distress if the options for successful intervention are limited or incompatible with the pa-
tient’s needs or desires.
Stigmatisation
A major burden for people with diabetes is that the disease is often considered the fault of the patient. This is particularly 
true for type 2 diabetes, as it is often labelled as ‘just’ a lifestyle disease. Clinical care of those with diabetes often 
results in a singular approach to treatment, regardless of their specific needs, life situation and other conditions. A 
clinical process that makes diagnosis more precise and includes a patient-oriented evaluation and response to needs 
has the potential to lessen stigma and reduce associated distress.
Text box 5: Precision medicine approaches to lessen treatment burden 
and improve mental health quality of life
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shared decision making will be needed to translate evidence
for precision diabetes medicine into individualised diabetes
care, accounting for patient preferences and behaviours, health
literacy and socioeconomic considerations. Pragmatic studies
of decision support systems utilising rich information in these
healthcare systems, particularly those with biobank-linked
electronic healthcare records, are needed to guide implemen-
tation of precision diabetes medicine into clinical practice and
to generate the much-needed cost-efficacy data for broader
adoption.
Building partnerships
Partnerships must be established between the scientific
community, patients, healthcare systems, providers, payors,
industry and regulatory bodies involved in the development,
evaluation, approval, adoption and implementation of preci-
sion diagnostics, monitoring and therapeutics that are deemed
acceptable for safe, efficacious and cost-effective use in preci-
sion diabetes care. Making the most of the opportunities
offered by precision diabetes medicine will require many
different stakeholders to form highly effective partnerships.
Without networks of partnerships that span academic institu-
tions, corporations, payors, regulators and medical and public
interest groups with shared understanding and vision (Fig. 5),
precision diabetes medicine is destined to fail. Partners in
making precision diabetes medicine a reality include:
– People with diabetes. People with diabetes are the most
important stakeholders. In Western countries, between
1:10 and 1:20 people have diabetes, while in other parts
of the world, diabetes is more prevalent (1:3 in some
middle-eastern populations [133], and 1:2 in some
Native American tribes [132]). The precision approach
to diabetes will require effective patient-facing, bi-
directional communication strategies that explain what
precision medicine is and how it works. People with
diabetes should be invited to contribute to research
through advisory and advocacy positions, postgraduate
educational programmes for clinicians, and play a central
role in discussions with politicians, regulators and payors.
– Regulatory agencies. The transition from current diabetes
clinical practice to a precision medicine approach will
have important implications for the development,
prescription, and regulation of diagnostics and therapeu-
tics. Involvement of regulators at the earliest stages of the
precision diabetes medicine workflow will be critical to
the successful implementation of the precision approach.
Recognising these challenges, the US FDA and the
European Medicines Agency (EMA) have initiated
discussions relating to standards for evidence and the
design of future clinical trials for precision diabetes medi-
cine [134].
– Payors. Payment for medical care related to diabetes
varies greatly, including between regions within
countries, with costs for diabetes often hidden in
other areas of medical care. Fragmentation of sites
of delivery for diabetes care and its costs directly
impact payment policies. There is evidence in the
case of monogenic diabetes that a precision medi-
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prevention, of complications (the major contributor
to diabetes costs) through precision diabetes medi-
cine may be the strongest driver for adoption.
– Product manufacturers. Diabetes technology, including
the development of wearable devices for glucose moni-
toring and for regulating insulin infusions (i.e., the artifi-
cial pancreas), has developed rapidly and is an example of
widespread personalised diabetes medicine. Technology
and pharmaceutical implementation is currently at a pre-
precision level, and treatment guidelines are quite gener-
ic. The European Federation of Pharmaceutical Industries
and Associations (EFPIA) Diabetes Platform, in which
six leading pharmaceutical companies are developing
shared policy goals focused on improving diabetes clini-
cal outcomes, has initiated multiple projects with strong
precision diabetes medicine agendas, with other public–
private partnerships focused on precision diabetes medi-
cine underway [136].
– Private and public supporters of research. Support for
diabetes research funding has struggled as its priority
has fallen among the general public and some political
decisionmakers, where cancer and cardiovascular disease
rank consistently higher than diabetes on the public agen-
da. For precision diabetes medicine to meaningfully
improve the lives of patients, it will be necessary to build
highly effective networks of key stakeholders, such that
common agendas are agreed to and funding for research
and implementation is made available. This in turn
requires that the evidence justifying a precision diabetes
medicine approach is clearly articulated to all major deci-
sion makers, including funders.
– Clinicians and professional organisations. Medical care
for the person with diabetes involves a wide-spectrum of
healthcare providers, including tertiary and secondary
specialists, general internists, primary care doctors,
nurses, dietitians, podiatrists, pharmacists, and other para-
medical professionals. Several organisations are engaged
in the PMDI (ADA, EASD, NIDDK) and representatives
of professional bodies in Asia, Africa and elsewhere are
being engaged by the PMDI to ensure global impact.
Tailoring educational modules and content to different
professional and cultural settings is ideally suited to these
partner organisations.
– General public. The enormous burden that diabetes
places on many healthcare systems is usually shouldered
by the general public, owing to the high costs of treating
the disease and loss of public revenue through decreased
productivity. The effective implementation of precision
prevention will require that the general public embraces
the approach and that those in greatest need can access
precision prevention programmes. Diabetes messaging
for the general public can be modelled on precision
oncology, for which public advocacy and engagement
have been successful, effectively utilising social media
as well as traditional media to communicate not only its
strengths and weaknesses but also its benefits and risks.
Summary and future perspectives
Precision diabetes medicine has found a firm foothold in the
diagnosis and treatment of monogenic diabetes, while the
application of precision medicine to other types of diabetes
is at this time aspirational, rather than standard of care. The
ability to integrate the diagnosis of monogenic diabetes into
routine clinical care is one example where diagnostics are
essential and meet many of the characteristics of the ideal test.
Despite an excellent diagnostic paradigm, there are no known
avenues for prevention in monogenic diabetes, although care-
ful monitoring in presymptomatic variant carriers may lead to
early detection of diabetes and rapid treatment.
Future precision diabetes medicine approaches are likely to
include diagnostic algorithms for defining diabetes subtypes
in order to decide the best interventional and therapeutic
approaches. The scope and potential for precision treatment
in diabetes is vast, yet deep understanding is lacking. It will be
imperative to determine when and how the application of
therapeutics in precision diabetes medicine improves
outcomes in a cost-effective fashion.
There are many important stakeholders whose engagement
will be necessary for the implementation of precision diabetes
medicine to succeed (Fig. 5). Progress in translating advances
in biology and technology will be governed by the identifica-
tion, accurate measurement and scalable deployment of agents
for diagnosis and therapy, so broad stakeholder engagement is
essential. It is crucial that precision approaches are available to
the full diversity of human populations and societal contexts,
such that precision diabetes medicine does not widen health
disparity but achieves the greatest benefits to all individuals
and society as a whole. Highly functional partnerships with
patient representatives and public organisations will be
required to reap the benefits of precision diabetes medicine.
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